Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan;32(1):13-19.
doi: 10.1097/CCO.0000000000000593.

Novel therapeutic options for radioiodine-refractory thyroid cancer: redifferentiation and beyond

Stefania Bulotta  1 , Marilena Celano  1 , Giuseppe Costante  1   2 , Diego Russo  1
Affiliations
Review

Novel therapeutic options for radioiodine-refractory thyroid cancer: redifferentiation and beyond

Stefania Bulotta et al. Curr Opin Oncol. 2020 Jan.

Abstract

Purpose of review: Radioiodine-refractory thyroid cancers represent the main cause of thyroid cancer-related death. At present, targeted therapies with multikinase inhibitors represent a unique therapeutic tool, though they have limited benefit on patient survival and severe drug-associated adverse events. This review summarizes current treatment strategies for radioiodine-refractory thyroid cancer and focuses on novel approaches to redifferentiate thyroid cancer cells to restore responsiveness to radioiodine administration.

Recent findings: We summarize and discuss recent clinical trial findings and early data from real-life experiences with multikinase-inhibiting drugs. Possible alternative strategies to traditional redifferentiation are also discussed.

Summary: The current review focuses primarily on the major advancements in the knowledge of the pathophysiology of iodine transport and metabolism and the genetic and epigenetic alterations occurring in thyroid neoplasia as described using preclinical models. Results of clinical studies employing new compounds to induce thyroid cancer cell redifferentiation by acting against specific molecular targets are also discussed. Finally, we describe the current scenario emerging from such findings as well as future perspectives.

PubMed Disclaimer

References

    1. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016; 26:1–133.
    1. Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006; 91:2892–2899.
    1. Durante C, Costante G, Filetti S. Differentiated thyroid carcinoma: defining new paradigms for postoperative management. Endocr Relat Cancer 2013; 20:R141–R154.
    1. Jin Y, Van Nostrand D, Cheng L, et al. Radioiodine refractory differentiated thyroid cancer. Crit Rev Oncol Hematol 2018; 125:111–120.
    1. Lamartina L, Durante C, Filetti S, et al. Low-risk differentiated thyroid cancer and radioiodine remnant ablation: a systematic review of the literature. J Clin Endocrinol Metab 2015; 100:1748–1761.

MeSH terms

Substances